Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma

Published:2017-06-01 Issue:1 Volume:3 Page:
ISSN:2057-3804
Container-title:Cardio-Oncology
language:en
Short-container-title:Cardio-Oncology

Author:

Chen John H.,Lenihan Daniel J.,Phillips Sharon E.,Harrell Shelton L.,Cornell Robert F.

Publisher

Springer Science and Business Media LLC

Subject

Materials Science (miscellaneous)

Link

http://link.springer.com/content/pdf/10.1186/s40959-017-0023-9.pdf

Reference30 articles.

1. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet (London, England). 2009;374(9686):324–39.

2. Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119(19):4375–82.

3. Rajkumar SV. Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? Hematol Am Soc Hematol Educ Program. 2012;2012:354–61.

4. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012;119(24):5661–70.

5. Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, et al. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012;12(5):310–8.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms;Journal of Molecular and Cellular Cardiology;2024-09

2. Recent Advances in Serum Biomarkers for Cardiological Risk Stratification and Insight into the Cardiac Management of the Patients With Hematological Malignancies Treated With Targeted Therapy;Cureus;2023-11-30

3. Targeting endothelial vascular cell adhesion molecule-1 in atherosclerosis: drug discovery and development of vascular cell adhesion molecule-1–directed novel therapeutics;Cardiovascular Research;2023-08-18

4. Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy;Current Problems in Cardiology;2023-03

5. Cardiac Adverse Events Associated with Multiple Myeloma Patients Treated with Proteasome Inhibitors;Oncology;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3